CAJ | 학술논문

目的：探讨拉米夫定联合异甘草酸镁在非小细胞肺癌（ NSCLC ）合并慢性乙型肝炎（ CHB ）患者化疗过程中的临床治疗价值。方法将105例NSCLC合并CHB患者分为观察组（n＝57）与对照组（n＝48），观察组在化疗基础上联合使用拉米夫定、异甘草酸镁，对照组单纯接受化疗。结果①第1次入院化疗时，2组患者丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、总胆红素（TBIL）、前白蛋白（PA）、乙型肝炎病毒脱氧核糖核酸（HBV DNA）相比，差异均无统计学意义（P＞0．05）。第2～4次入院化疗时，观察组ALT、AST、TBIL、HBV DNA显著低于对照组（P＜0．05），PA显著高于对照组（P＜0．05）。②观察组完成4个化疗周期总时间显著低于对照组（P＜0．05）。结论拉米夫定联合异甘草酸镁可显著改善NSCLC合并CHB患者化疗过程中的肝功能，同时还可以降低血清HBV DNA，缩短治疗时间，值得临床应用与推广。
목적：탐토랍미부정연합이감초산미재비소세포폐암（ NSCLC ）합병만성을형간염（ CHB ）환자화료과정중적림상치료개치。방법장105례NSCLC합병CHB환자분위관찰조（n＝57）여대조조（n＝48），관찰조재화료기출상연합사용랍미부정、이감초산미，대조조단순접수화료。결과①제1차입원화료시，2조환자병안산안기전이매（ALT）、천동안산안기전이매（AST）、총담홍소（TBIL）、전백단백（PA）、을형간염병독탈양핵당핵산（HBV DNA）상비，차이균무통계학의의（P＞0．05）。제2～4차입원화료시，관찰조ALT、AST、TBIL、HBV DNA현저저우대조조（P＜0．05），PA현저고우대조조（P＜0．05）。②관찰조완성4개화료주기총시간현저저우대조조（P＜0．05）。결론랍미부정연합이감초산미가현저개선NSCLC합병CHB환자화료과정중적간공능，동시환가이강저혈청HBV DNA，축단치료시간，치득림상응용여추엄。
Objective To investigate the efficacy of lamivudine combined with magnesium isoglycyrrhizinate in the treat -ment of non-small cell lung cancer ( NSCLC) patients with chronic hepatitis B ( CHB) during chemotherapy .Methods 105 cases of NSCLC patients with CHB were divided into the observation group (n=57) and the control group(n=48),and the observation group received chemotherapy combined with lamivudine and magnesium isoglycyrrhizinate ,2while the control group was given chemotherapy only.Results ①During the 1st course of chemotherapy,there were no significant differences in the alanine amin-otransferase ( ALT) ,aspartate aminotransferase ( AST) ,total bilirubin ( TBIL) ,prealbumin ( PA) ,hepatitis B virus deoxyribonu-cleic acid (HBV DNA) between the 2 groups(P>0.05).During the 2nd,23rd and 4th course of chemotherapy,the ALT,AST, TBIL,HBV DNA in the observation group were significantly lower than those of the control group respectively (P<0.05),while the PA was significantly higher than that of the control group (P<0.05).②The total time of 4 courses of chemotherapy of the ob-servation group was significantly lower than that of the control group (P<0.05).Conclusion Lamivudine combined with mag-nesium isoglycyrrhizinate can improve liver function of NSCLC patients with CHB during chemotherapy ,as well as reduce serum HBV DNA and shorten the treatment time .It is worthy of clinical application .